Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 7/20 | 0.44 |
| ▸ | FNTB | P49356 | 7/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13396662 | 0.84 | FOLH1 (0.36) | FNTAFNTBMAPK1LMNACA2 | |
| SCHEMBL13396768 | 0.84 | FNTA (0.37) | FNTAFNTBPGGT1BNOD1FOLH1 | |
| SCHEMBL13396652 | 0.83 | FNTA (0.49) | FNTAFNTBPGGT1BMAPK1NOD1 | |
| SCHEMBL13396691 | 0.83 | SLC6A5 (0.46) | NOD1CA2CA1FOLH1 | |
| SCHEMBL13396744 | 0.82 | NOD1 (0.44) | FNTAFNTBPGGT1BNOD1FOLH1 | |
| SCHEMBL13396651 | 0.81 | FNTA (0.52) | FNTAFNTBPGGT1BMAPK1NOD1 | |
| SCHEMBL13396707 | 0.79 | NOD1 (0.39) | FNTAFNTBPGGT1BNOD1 | |
| SCHEMBL16124693 | 0.78 | PTGS2 (0.33) | — | |
| SCHEMBL13396825 | 0.78 | NOD1 (0.36) | FNTAFNTBPGGT1BNOD1FOLH1 | |
| SCHEMBL20104860 | 0.77 | ALDH1A1 (0.36) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266820-B2 | Nitric oxide donor compounds | NICOX SCIENCE IRELAND (IE) | 2016-02-23 | — | — | US | disclosed |
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | FNTA 452/4885FNTB 802/4885PGGT1B 3081/4885 |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | FNTA 476/4885FNTB 850/4885PGGT1B 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.